Finland· FI-REL-REL53322
Trogarzo
A ibalizumab product containing ibalizumab, registered in Finland by Theratechnologies Europe Limited. The same ATC class is registered in 4 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Ibalizumab is registered in 4 of 19 countries.
Countries holding a registration under ATC J05AX23 (ibalizumab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 4 of them publish a price we can compare per daily dose
Ibalizumab · ATC J05AX23
4 / 19 countries
- Belgiumprice
- Finlandprice
- Spainprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Ibalizumab
- Manufacturer
- Theratechnologies Europe Limited
- Country
- Finland (FI)
- ATC code
- J05AX23
- ATC class
- Ibalizumab
- Defined daily dose
- 57 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ibalizumab in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f2e75e55-c8d1-4e93-86a1-97c40e761ca0 GET /v1/drugs/f2e75e55-c8d1-4e93-86a1-97c40e761ca0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "200 mg",
"atc_label": "ibalitsumabi",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/19/1359/001",
"fimea_rel_id": "REL53322",
"authorised_at": "2019-09-26"
}See everything about ibalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.